AUTHOR=Mendrinou Effrosyni , Mashaly Mohamed Elsayed , Al Okily Amir Mohamed , Mohamed Mohamed Elsayed , Refaie Ayman Fathi , Elsawy Essam Mahmoud , Saleh Hazem Hamed , Sheashaa Hussein , Patrinos George P. 

TITLE=CYP3A5 Gene-Guided Tacrolimus Treatment of Living-Donor Egyptian Kidney Transplanted Patients

JOURNAL=Frontiers in Pharmacology

VOLUME=11

YEAR=2020

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2020.01218

DOI=10.3389/fphar.2020.01218

ISSN=1663-9812

ABSTRACT=<sec><title>Background</title><p>Tacrolimus is an approved first-line immunosuppressive agent for kidney transplantations. Part of interindividual and interethnic differences in the response of patients to tacrolimus is attributed to polymorphisms at CYP3A5 metabolic enzyme. <italic>CYP3A5</italic> gene expression status is associated with tacrolimus dose requirement in renal transplant recipients.</p></sec><sec><title>Materials and Methods</title><p>In this study, we determined the allelic frequency of <italic>CYP3A5*3</italic> in 76 renal transplanted patients of Egyptian descent. Secondly, we evaluated the influence of the <italic>CYP3A5</italic> gene variant on tacrolimus doses required for these patients as well on dose-adjusted tacrolimus trough-concentrations.</p></sec><sec><title>Results</title><p>The <italic>CYP3A5*3</italic> variant was the most frequent allele detected at 85.53%. Additionally, our results showed that, mean tacrolimus daily requirements for heterozygous patients (<italic>CYP3A5*1/*3</italic>) were significantly higher compared to homozygous patients (<italic>CYP3A5*3/*3</italic>) during the first year after kidney transplantation.</p></sec><sec><title>Conclusion</title><p>This is the first study in Egypt contributing to the individualization of tacrolimus dosing in Egyptian patients, informed by the <italic>CYP3A5</italic> genotype.</p></sec>